SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001144204-17-049719
Filing Date
2017-09-26
Accepted
2017-09-26 16:01:50
Documents
1
Group Members
CELGENE CORP

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 5 TO SCHEDULE 13D v475740_sc13da.htm SC 13D/A 82178
  Complete submission text file 0001144204-17-049719.txt   83727
Mailing Address 400 DEXTER AVENUE NORTH, SUITE 1200 SEATTLE WA 98109
Business Address 400 DEXTER AVENUE NORTH, SUITE 1200 SEATTLE WA 98109 2065821600
Juno Therapeutics, Inc. (Subject) CIK: 0001594864 (see all company filings)

IRS No.: 463656275 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88476 | Film No.: 171102169
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address AON HOUSE 30 WOODBOURNE AVENUE PEMBROKE D0 HM 08
Business Address AON HOUSE 30 WOODBOURNE AVENUE PEMBROKE D0 HM 08 4412964803
Celgene Switzerland LLC (Filed by) CIK: 0001661486 (see all company filings)

IRS No.: 475587373 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A